MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma
Go back to MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma| MEI PHARM (NASDAQ: MEIP) | Delayed: 3.07 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.07 | 52 Week High | $2.28 | |||
| Open | $3.07 | 52 Week Low | $0.87 | |||
| Day High | $3.07 | P/E | N/A | |||
| Day Low | $3.07 | EPS | $-0.88 | |||
| Volume | 298,686 | |||||
